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There are reports about the strong correlation between pancreatic function and the
CFTR genotype, whereas others clinical signs could be different in patients with
the same genotype. Because of this, it has been proposed the presence of modiﬁers
genes that inﬂuence the severity of CF. The aim of this study is to determine the
frequency of allelic variants of the genes TNF-a, MBL, a1AT, a1ACT, b-2AD,
IL-10, NOS3 and their association with pulmonary disease. 60 patients with CF
were included, 15 SNPs were analyzed by allelic discrimination with Taq-Man
probes. Pulmonary phenotype was determined by positive Pseudomona cultures,
health condition, age at diagnostic and death, beginning of symptoms, ﬁrst positive
Pae culture, Brasﬁeld score and the best FEV1 in three years. The association of
SNPs with the pulmonary disease was analyzed with the statistic program SPSS,
an a value of p< 0.05. The distribution of genotypes was in equilibrium with
Hardy-Weinberg. The frequency of allelic variants does not show differences with
the literature reports. On the other hand signiﬁcant differences were found in the
variables MBL-550 with health condition, and a1ACT-15Thr>Ala with age at death
and Brasﬁeld score, and a1AT-Z with best FEV1 in three years. This is the ﬁrst
report about the association of some SNPs of speciﬁc response with variables of
pulmonary phenotype among Mexican patients with CF. Our results suggest that
genomic analysis of patients with CF could be necessary for predict the clinical
evolution of the disease and to establish an individualized treatment of patients.
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Chronic Obstructive Pulmonary Disease (COPD) is a complex disease inﬂuenced by
genetic and environmental factors. Different genetic variants may alter or modulate
processes that could lead to initiation and progression of COPD pathogenesis.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein is an
important component of the lung tissue homeostasis, involved in the regulation of
the rate of mucociliary clearance. This study was undertaken to assess the role of
F508del mutation and three common CFTR variants, M470V, IVS8−5T and R75Q,
in COPD development and modulation. The presence of these variants was analyzed
in 86 patients diagnosed with COPD and 102 control subjects and obtained results
were subjected to statistical analysis.
No associations were detected between COPD development, onset of the disease and
tested CFTR alleles and genotypes. However, VV470 genotype was associated with
mild/moderate COPD stages in comparison to severe/very severe ones (OR= 0.29,
95%CI = 0.11−0.80, p = 0.016). Our study showed that patients with VV470
genotype had a 3.4-fold decreased risk for the appearance of severe/very severe
COPD symptoms and the obtained results indicate that this genotype may have
a protective role. Bearing in mind that advanced COPD is linked with clinical
complications and diminished quality of life, this observation could be of special
importance for prevention in mild/moderate COPD patients.
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Recent investigations have been established that polymorphic variants in genes
besides CFTR play an important role in determining severity of CF disease. We
analyzed the association of CF clinical features and polymorphisms/mutations in
6 genes: VNTR polymorphism in intron 4 of eNOS gene; −308G−A of TNFA
gene; +252A−G of LTA gene; 10 kbp deletion polymorphism of GSTM1 gene;
promoter polymorphism −221G−C and 3 mutations in exon 1, G54D, G57E, R52C,
of MBL2 gene; C242Y and H63D of HFE gene in 148 CF patients homozygous
for F508del mutation. Patients were categorized into groups according to their
genotypes of analyzing genes. The age of lung and intestinal disease manifestation,
the age of diagnosis, severity of disease progression, FVC and FEV1 indexes,
height-weight indexes, S. aureus and P. aeruginosa colonization, liver disease and
meconium ileus (MI) were evaluated. We revealed the association of eNOS, MBL2
and HFE genes and disease severity. Patients carrying A allele of the eNOS gene
(genotypes A/A and A/B) had signiﬁcantly lower pulmonary function (p< 0.05);
airways colonization by P. aeruginosa were diagnosed signiﬁcantly earlier in patients
with MBL-insufﬁcient alleles (p< 0.02); liver cirrhosis was more frequent among
patients with B/B genotype of the eNOS gene (p< 0.05); and meconium ileus was
more frequent in patients carrying D63 allele of HFE gene (p< 0.05). Associations
between phenotypic characteristic of CF and analyzed polymorphisms of TNFA,
LTA and GSTM1 genes were not found.
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Cystic ﬁbrosis (CF) is a lethal, multi-system autosomal recessive genetic disorder
primarily affecting Caucasian populations, caused by mutations in the CFTR gene.
Severity of clinical presentation in CF, particularly the pulmonary manifestation, are
highly variable. This variability is only partially explained by allelic heterogeneity
at the CFTR gene. Literature data suggest that the severity in CF may be correlated
with other genetic factors. Two polymorphisms (−509C/T and Leu10Pro) of the
TGFB1 gene, which encodes for a cytokine involved in inﬂammation and tissue
repair and expressed by several cells, have been associated to a more severe
CF pulmonary manifestation in the American population (Drumm et al, NEJM
353:1443; 2005). We here report the results of association analyses of three TGFb1
polymorphisms (−509C/T, Leu10Pro, Arg25Pro) in Italian patients. Eighty family
trios with a CF child and 52 unrelated CF patients were collected through the
Veneto Regional CF Centre of Verona. All the patients were clinically evaluated
for respiratory parameters, gastrointestinal and nutritional status parameters, and
other clinical variables related to the common CF complications (diabetes, DIOS,
etc). TDT test result showed evidence of association between Pro25 and FEV1
(p = 0.018). No association was found among other polymorphisms and studied
clinical parameters. Single locus and haplotype analyses performed in all the
unrelated CF patients conﬁrm the association of TGFB1 gene polymorphisms with
FEV1%.
These results compared to literature data indicate that further studies are necessary
to characterized the involvement of TGFB1 gene as modiﬁer of disease severity
in CF.
